<DOC>
	<DOCNO>NCT01174355</DOCNO>
	<brief_summary>A multicenter , open label , escalate dose study assess tolerability safety explore efficacy pharmacokinetics ND0801 adult patient attention deficit/hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>A Study ND0801 Attention Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Outpatients . Men woman 1855 year age . Primary DSMIV diagnosis adult ADHD confirm senior physician Capable willing provide inform consent Able adhere treatment schedule , withdrawal ongoing pharmacotherapy treatment ADHD prior begin study treatment study drug treatment . Subjects must able read , hear , write speak local language . Subject sign write informed consent participate study . Unstable significant medical disorder . Current ( within 12 month baseline ) primary secondary depression . History substance abuse dependence within past 6 month Any psychotic disorder ( lifetime ) , include schizoaffective disorder , major depression psychotic feature Bipolar disorder Eating disorder Obsessive compulsive disorder Posttraumatic stress disorder Current generalize anxiety disorder Presence personality disorder Individuals significant neurological disorder . Use investigational drug within 4 week randomization visit Known suspect pregnancy Women breastfeed Women childbearing potential use medically accept form contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>